Lietuvos sveikatos mokslu universiteto Kauno ligonine
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Department of Internal Diseases at Lietuvos sveikatos mokslu universiteto Kauno ligonine is advancing cardiovascular research by testing a new anticoagulant aimed at reducing stroke and systemic embolism in patients with atrial fibrillation.
- Evaluation of asundexian versus standard therapy
- Safety and bleeding risk assessment
- Long‑term prevention of systemic embolism
These trials seek to provide safer alternatives to existing blood thinners and to enhance risk‑management strategies for heart rhythm disorders.
Digestive System Diseases
In the field of digestive system diseases, investigators are evaluating a novel oral therapy for patients with moderate to severe ulcerative colitis, focusing on achieving endoscopic improvement and symptomatic remission.
- Comparison of novel therapy with placebo
- Assessment of mucosal healing
- Patient‑reported outcome measures
The purpose of this work is to broaden treatment options and improve quality of life for individuals living with this chronic inflammatory condition.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Neurocrine Biosciences Inc.2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Neurocrine Biosciences Inc.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 79 other sites in Lithuania
Therapeutic Area Benchmark — Lithuania
Select a therapeutic area to compare against other sites in Lithuania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Lithuania
Market Share
Country: Lithuania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lietuvos sveikatos mokslu universiteto Kauno ligonine
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX). | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 3 | Unknown | 2022-11-24 | 2025-11-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.